Literature DB >> 34390784

Patch testing with ammonium persulfate: The North American Contact Dermatitis Group Experience, 2015-2018.

Erin M Warshaw1, Jenna L Ruggiero2, Joel G DeKoven3, Melanie D Pratt4, Jonathan I Silverberg5, Howard I Maibach6, Kathryn A Zug7, Amber R Atwater8, James S Taylor9, Margo J Reeder10, Denis Sasseville11, Joseph F Fowler12, Anthony F Fransway13, Donald V Belsito14, Vincent A DeLeo15, Marie-Claude Houle16, Cory A Dunnick17.   

Abstract

BACKGROUND: Ammonium persulfate (APS), an oxidizing agent used in hair products, manufacturing, and pool/spa water, can cause skin reactions, including allergic contact dermatitis.
OBJECTIVE: To characterize positive patch test reactions to APS (2.5% petrolatum).
METHODS: Retrospective analysis of patients tested to the North American Contact Dermatitis Group screening series from 2015 to 2018.
RESULTS: Of 10,526 patients, 193 (1.8%) had positive patch test reactions to APS. Compared with APS-negative patients, APS-positive patients were significantly more likely to be male (43.2% vs 28.0%; P < .0001); have primary hand dermatitis (30.2% vs 22.0%; P = .0064), scattered generalized dermatitis (25.5% vs 17.9%; P = .0064), or trunk dermatitis (8.9% vs 4.9%; P = .0123); and have dermatitis that is occupationally related (22.2% vs 10.9%; P < .0001). More than half of the APS-positive reactions were currently relevant (57.0%); 19 (9.8%) were related to occupation, especially hairdressers (68.4%). Swimming pools/spas (23.3%) and hair care products (19.2%) were the most common sources of APS. LIMITATIONS: Immediate reactions and follow-up testing were not captured.
CONCLUSION: The proportion of patients positive to APS was 1.8%. APS positivity was significantly associated with male sex and hand dermatitis. Swimming pool/spa chemicals were important sources of APS exposure.
Copyright © 2021 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  allergic contact dermatitis; ammonium persulfate; contact allergy; patch tests

Mesh:

Substances:

Year:  2021        PMID: 34390784     DOI: 10.1016/j.jaad.2021.08.005

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   15.487


  1 in total

Review 1.  Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma.

Authors:  Hikaru Nanamori; Yu Sawada
Journal:  Int J Mol Sci       Date:  2022-01-20       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.